Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | IDH2 | P48735 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | CTSL | P07711 | 1/20 | 0.45 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3459440 | 0.84 | GAA (0.48) | GAAHTTPOLBKMT2ALMNA | |
| SCHEMBL967263 | 0.82 | LMNA (0.52) | GAAHTTPOLBKMT2ALMNA | |
| SCHEMBL967255 | 0.79 | SMN1; SMN2 (0.57) | GAAHTTPOLBKMT2ALMNA | |
| SCHEMBL4714647 | 0.75 | GAA (0.57) | GAAHTTPOLBKMT2ALMNA | |
| SCHEMBL837824 | 0.75 | SMN1; SMN2 (0.70) | GAAHTTPOLBKMT2ALMNA | |
| SCHEMBL29446980 | 0.75 | SMN1; SMN2 (0.70) | GAAHTTPOLBKMT2ALMNA | |
| SCHEMBL18838552 | 0.75 | SMN1; SMN2 (0.70) | GAAHTTPOLBKMT2ALMNA | |
| SCHEMBL965698 | 0.74 | GAA (0.56) | GAAHTTPOLBKMT2ALMNA | |
| SCHEMBL3459439 | 0.74 | KMT2A (0.51) | GAAHTTPOLBKMT2ALMNA | |
| SCHEMBL963073 | 0.73 | SMN1; SMN2 (0.57) | GAAHTTKMT2ALMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110021525-A1 | P70S6 Kinase Modulators and Method of Use | EXELIXIS, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| US-7816353-B2 | P70S6 kinase modulators and method of use | EXELIXIS, INC. (US) | 2010-10-19 | — | — | US | disclosed |
| US-20070208020-A1 | P70S6 Kinase Modulators And Method Of Use | EXELIXIS, INC. | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021525-A1 | P70S6 Kinase Modulators and Method of Use | EEF2K, RPS6KA3, MTOR | GAA 950/4885HTT 2468/4885POLB 1908/4885 |
| US-20070208020-A1 | P70S6 Kinase Modulators And Method Of Use | EEF2K, RPS6KA3, MTOR | GAA 950/4885HTT 2468/4885POLB 1908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.